Piramal

Executive Summary

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) offering end-to-end services across the drug lifecycle, including drug discovery, development, and manufacturing for small molecules, biologics, and specialized modalities such as Antibody Drug Conjugates (ADCs) and peptides. Headquartered in London, UK, the company operates 15 facilities worldwide and serves over 500 pharmaceutical and biotech customers. Founded in 2020, Piramal has rapidly established itself as a key player in the CDMO space, leveraging its integrated platform to support clients from early-stage development to commercial manufacturing. Looking ahead, Piramal is poised for growth driven by increasing demand for CDMO services, particularly in the biologics and ADC segments. The company's recent strategic investments in capacity expansion and technology advancements position it to capture market share. Key catalysts include the ramp-up of its ADC manufacturing capabilities, potential new long-term contracts with large pharma, and expansion into high-growth areas like peptide therapeutics. With its diversified service offerings and global footprint, Piramal is well-positioned to benefit from the outsourcing trend in the pharmaceutical industry.

Upcoming Catalysts (preview)

• Q4 2026Expansion of ADC manufacturing capacity85% success
• Q1 2027Major long-term contract win with top pharma60% success
• Q2 2027Launch of new peptide production line75% success